303 related articles for article (PubMed ID: 18845199)
1. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines.
Verstraeten T; Descamps D; David MP; Zahaf T; Hardt K; Izurieta P; Dubin G; Breuer T
Vaccine; 2008 Dec; 26(51):6630-8. PubMed ID: 18845199
[TBL] [Abstract][Full Text] [Related]
2. Rebuttal Letter to the Letter to the Editor to "Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines" by T. Verstraeten et al.
Verstraeten T
Vaccine; 2009 Apr; 27(19):2530. PubMed ID: 19428857
[No Abstract] [Full Text] [Related]
3. The safety evaluation of adjuvants during vaccine development: the AS04 experience.
Garçon N; Segal L; Tavares F; Van Mechelen M
Vaccine; 2011 Jun; 29(27):4453-9. PubMed ID: 21527299
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls.
Medina DM; Valencia A; de Velasquez A; Huang LM; Prymula R; García-Sicilia J; Rombo L; David MP; Descamps D; Hardt K; Dubin G;
J Adolesc Health; 2010 May; 46(5):414-21. PubMed ID: 20413076
[TBL] [Abstract][Full Text] [Related]
5. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.
David MP; Van Herck K; Hardt K; Tibaldi F; Dubin G; Descamps D; Van Damme P
Gynecol Oncol; 2009 Dec; 115(3 Suppl):S1-6. PubMed ID: 19217149
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety of an experimental adjuvanted hepatitis B candidate vaccine in liver transplant patients.
Nevens F; Zuckerman JN; Burroughs AK; Jung MC; Bayas JM; Kallinowski B; Rivas EF; Duvoux C; Neuhaus P; Saliba F; Buti M; Zarski JP; Pons F; Vanlemmens C; Hamtiaux V; Stoffel M
Liver Transpl; 2006 Oct; 12(10):1489-95. PubMed ID: 16964595
[TBL] [Abstract][Full Text] [Related]
7. AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention.
Schwarz TF
Expert Rev Vaccines; 2008 Dec; 7(10):1465-73. PubMed ID: 19053203
[TBL] [Abstract][Full Text] [Related]
8. Long-term immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in 10- to 14-year-old girls: open 6-year follow-up of an initial observer-blinded, randomized trial.
Schwarz TF; Huang LM; Lin TY; Wittermann C; Panzer F; Valencia A; Suryakiran PV; Lin L; Descamps D
Pediatr Infect Dis J; 2014 Dec; 33(12):1255-61. PubMed ID: 24978856
[TBL] [Abstract][Full Text] [Related]
9. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity.
Didierlaurent AM; Morel S; Lockman L; Giannini SL; Bisteau M; Carlsen H; Kielland A; Vosters O; Vanderheyde N; Schiavetti F; Larocque D; Van Mechelen M; Garçon N
J Immunol; 2009 Nov; 183(10):6186-97. PubMed ID: 19864596
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis of pregnancy outcomes in pooled randomized trials on a prophylactic adjuvanted glycoprotein D subunit herpes simplex virus vaccine.
Tavares F; Cheuvart B; Heineman T; Arellano F; Dubin G
Vaccine; 2013 Mar; 31(13):1759-64. PubMed ID: 23313657
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04.
Boland G; Beran J; Lievens M; Sasadeusz J; Dentico P; Nothdurft H; Zuckerman JN; Genton B; Steffen R; Loutan L; Van Hattum J; Stoffel M
Vaccine; 2004 Dec; 23(3):316-20. PubMed ID: 15530674
[TBL] [Abstract][Full Text] [Related]
12. MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database.
Pellegrini M; Nicolay U; Lindert K; Groth N; Della Cioppa G
Vaccine; 2009 Nov; 27(49):6959-65. PubMed ID: 19751689
[TBL] [Abstract][Full Text] [Related]
13. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems.
Garçon N; Van Mechelen M
Expert Rev Vaccines; 2011 Apr; 10(4):471-86. PubMed ID: 21506645
[TBL] [Abstract][Full Text] [Related]
14. Safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in adolescents aged 12-15 years: Interim analysis of a large community-randomized controlled trial.
Lehtinen M; Eriksson T; Apter D; Hokkanen M; Natunen K; Paavonen J; Pukkala E; Angelo MG; Zima J; David MP; Datta S; Bi D; Struyf F; Dubin G
Hum Vaccin Immunother; 2016 Dec; 12(12):3177-3185. PubMed ID: 27841725
[TBL] [Abstract][Full Text] [Related]
15. Safety of the AS04-adjuvanted human papillomavirus (HPV)-16/18 vaccine in adolescents aged 12-15 years: end-of-study results from a community-randomized study up to 6.5 years.
Bi D; Apter D; Eriksson T; Hokkanen M; Zima J; Damaso S; Soila M; Dubin G; Lehtinen M; Struyf F
Hum Vaccin Immunother; 2020 Jun; 16(6):1392-1403. PubMed ID: 31829767
[TBL] [Abstract][Full Text] [Related]
16. Preclinical development of AS04.
Garçon N
Methods Mol Biol; 2010; 626():15-27. PubMed ID: 20099118
[TBL] [Abstract][Full Text] [Related]
17. Recombinant Hepatitis B Vaccine Adjuvanted With AS04 in Dialysis Patients: A Prospective Cohort Study.
Fabrizi F; Tarantino A; Castelnovo C; Martin P; Messa P
Kidney Blood Press Res; 2015; 40(6):584-92. PubMed ID: 26566033
[TBL] [Abstract][Full Text] [Related]
18. Response to "Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines" by Verstraeten et al.
Hildesheim A; Schiffman M; Solomon D; Wacholder S; Rodriguez AC; Herrero R
Vaccine; 2009 Apr; 27(19):2529. PubMed ID: 19186195
[No Abstract] [Full Text] [Related]
19. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine administered according to an alternative dosing schedule compared with the standard dosing schedule in healthy women aged 15 to 25 years: results from a randomized study.
Esposito S; Birlutiu V; Jarcuska P; Perino A; Man SC; Vladareanu R; Meric D; Dobbelaere K; Thomas F; Descamps D
Pediatr Infect Dis J; 2011 Mar; 30(3):e49-55. PubMed ID: 21273939
[TBL] [Abstract][Full Text] [Related]
20. Autoimmune disorders after immunisation with Influenza A/H1N1 vaccines with and without adjuvant: EudraVigilance data and literature review.
Isai A; Durand J; Le Meur S; Hidalgo-Simon A; Kurz X
Vaccine; 2012 Nov; 30(49):7123-9. PubMed ID: 23022149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
